Natera (NTRA) Sec. and CLO Daniel Rabinowitz Sells $8.5M of Stock

Daniel Rabinowitz, the Secretary and Chief Legal Officer at Natera, Inc. (NasdaqGS: NTRA), sold 33,600 shares of the company on June 24, 2026. The shares were sold at an average price of $251.65, amounting to a total value of approximately $8.46 million. This transaction was part of a pre-planned trading strategy under a Rule 10b5-1 plan.

Insider Buying and Selling at Natera, Inc.

On June 24, 2026, Daniel Rabinowitz sold 33,600 shares of Natera, Inc., valued at around $8.46 million. This planned transaction was executed at an average price of $251.65 per share. Other recent insider activities include sales by Herm Rosenman and Jonathan Sheena, with transactions also executed under pre-planned trading arrangements.

Other Institutional Activity in Natera, Inc.

Among institutional investors, JPMorgan Chase & Co. added 532,333 shares, ending with 13,386,667 shares valued at about $2.5 billion, marking a 4.1% increase. Price T Rowe Associates increased its stake by 1,312,887 shares, holding 12,184,876 shares worth approximately $2.44 billion, a 12.1% rise. BlackRock, Inc. trimmed its position by 182,103 shares, leaving it with 10,677,338 shares valued at $2.14 billion, a 1.7% decrease. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions with 6,008,496 and 5,644,695 shares, respectively.

Natera, Inc. Stock Down 34.6%

As of Saturday, shares of Natera, Inc. (NasdaqGS: NTRA) traded near $264.70. The company has a market capitalization of $37.34 billion. Although it currently operates at a loss, its forward P/E ratio is not meaningful. The stock's 52-week range spans from $131.81 to $271.47, with a 50-day moving average of $211.31 and a 200-day moving average of $208.15. Natera maintains a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Recent Earnings

In its latest earnings report, Natera posted revenue of $2.50 billion, reflecting a year-over-year growth rate of 38.8%. The company, however, reported a net margin of -9.05%, and a return on equity of -15.02%. The next earnings announcement is scheduled for May 7, 2026.

Analysts Set New Price Targets

Analyst sentiment remains positive for Natera, with several firms reiterating their 'buy' ratings. On June 24, 2026, BTIG maintained a 'buy' rating with a price target of $275, while Barclays also maintained its 'buy' rating, setting a target of $260. Bernstein reiterated its 'buy' rating with a higher target of $310 on June 26, 2026. The consensus among 20 analysts is a 'buy' recommendation, with an average target price of $260.30.

About Natera, Inc.

Natera, Inc. is a healthcare company specializing in diagnostics and research, headquartered in Austin, Texas. It develops and markets a range of molecular testing services worldwide, including personalized cancer diagnostics and prenatal screening tests. The company was founded in 2003 and is led by CEO Steven Leonard Chapman. Natera employs over 6,000 people and partners with various laboratories and pharmaceutical companies.

Bottom Line

Daniel Rabinowitz's planned sale of Natera shares reflects routine insider trading activities at the company. Natera's financial position remains robust with significant revenue growth, although it is not yet profitable. Analysts continue to express confidence in the company's future prospects, maintaining 'buy' ratings and setting high price targets.